嵌合抗原受体（CAR）疗法需要驾驶执照吗？采用嵌合抗原受体重定向T细胞的过继性细胞疗法已引发严重不良事件。 - Suppr

Suppr

超能文献

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.

作者信息

Büning Hildegard, Uckert Wolfgang, Cichutek Klaus, Hawkins Robert E, Abken Hinrich

机构信息

Zentrum für Molekulare Medizin Köln and Klinik I für Innere Medizin, Uniklinik Köln, Cologne, Germany.

出版信息

Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131.

DOI:10.1089/hum.2010.131

PMID:20626322

Abstract

摘要

相似文献

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.嵌合抗原受体（CAR）疗法需要驾驶执照吗？采用嵌合抗原受体重定向T细胞的过继性细胞疗法已引发严重不良事件。

Hum Gene Ther. 2010 Sep;21(9):1039-42. doi: 10.1089/hum.2010.131.

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.采用基因工程 T 细胞的过继免疫疗法：嵌合抗原受体细胞外部分的 IgG1 Fc“间隔区”结构域的修饰可避免“脱靶”激活和非预期固有免疫反应的启动。

Gene Ther. 2010 Oct;17(10):1206-13. doi: 10.1038/gt.2010.91. Epub 2010 Jun 17.

Chimeric antigen receptors for T-cell based therapy.用于基于T细胞疗法的嵌合抗原受体。

Methods Mol Biol. 2012;907:645-66. doi: 10.1007/978-1-61779-974-7_36.

[Novel therapy for malignant lymphoma: adoptive immuno-gene therapy using chimeric antigen receptor(CAR)-expressing T lymphocytes].恶性淋巴瘤的新型疗法：使用表达嵌合抗原受体（CAR）的T淋巴细胞进行过继免疫基因治疗

Nihon Rinsho. 2014 Mar;72(3):547-52.

Adoptive cancer immunotherapy using genetically engineered designer T-cells: First steps into the clinic.使用基因工程设计T细胞的过继性癌症免疫疗法：迈向临床的第一步。

Curr Opin Mol Ther. 2010 Feb;12(1):55-63.

Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.针对B细胞非霍奇金淋巴瘤中CD38的嵌合受体激活T细胞介导的免疫疗法。

J Immunother. 2009 Sep;32(7):737-43. doi: 10.1097/CJI.0b013e3181adaff1.

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.用基因修饰的 T 细胞作为免疫疗法治疗表达 Lewis Y 抗原的多发性骨髓瘤和急性髓性白血病。

Gene Ther. 2010 May;17(5):678-86. doi: 10.1038/gt.2010.21. Epub 2010 Mar 4.

Genetic redirection of T cells for cancer therapy.基因重定向 T 细胞用于癌症治疗。

J Leukoc Biol. 2010 May;87(5):791-803. doi: 10.1189/jlb.1209824. Epub 2010 Feb 23.

Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.嵌合受体抗 CD19 或抗 CD38 联合利妥昔单抗的 T 细胞免疫治疗对 B 细胞非霍奇金淋巴瘤的协同和持续作用。

Br J Haematol. 2010 Oct;151(1):37-46. doi: 10.1111/j.1365-2141.2010.08297.x. Epub 2010 Jul 30.

The T-body approach: redirecting T cells with antibody specificity.T 细胞体方法：利用抗体特异性重定向 T 细胞。

Handb Exp Pharmacol. 2008(181):329-42. doi: 10.1007/978-3-540-73259-4_14.

引用本文的文献

Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy.肿瘤相关碳水化合物抗原嵌合抗原受体 T 细胞和双特异性抗体在抗肿瘤免疫治疗中的最新进展。

Semin Immunol. 2020 Feb;47:101390. doi: 10.1016/j.smim.2020.101390. Epub 2020 Jan 22.

Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering.可离子化脂质纳米颗粒介导的 mRNA 递送至人嵌合抗原受体 T 细胞工程。

Nano Lett. 2020 Mar 11;20(3):1578-1589. doi: 10.1021/acs.nanolett.9b04246. Epub 2020 Feb 5.

Current Perspectives in Cancer Immunotherapy.癌症免疫疗法的当前观点

Cancers (Basel). 2019 Sep 30;11(10):1472. doi: 10.3390/cancers11101472.

Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.癌症免疫疗法：临床革命的历史视角与新兴的临床前动物模型

Front Immunol. 2017 Aug 2;8:829. doi: 10.3389/fimmu.2017.00829. eCollection 2017.

Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer.双功能αHER2/CD3 RNA工程化的类CART人T细胞可特异性消除HER2阳性胃癌。

Cell Res. 2016 Jul;26(7):850-3. doi: 10.1038/cr.2016.81. Epub 2016 Jun 24.

Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.共表达的过氧化氢酶可保护嵌合抗原受体重定向T细胞以及旁观者细胞免受氧化应激诱导的抗肿瘤活性丧失。

J Immunol. 2016 Jan 15;196(2):759-66. doi: 10.4049/jimmunol.1401710. Epub 2015 Dec 16.

Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.针对表达叶酸受体的常见上皮癌，对有效的RNA嵌合抗原受体（CAR）T细胞疗法进行严格优化和验证。

Oncotarget. 2015 Oct 6;6(30):28911-28. doi: 10.18632/oncotarget.5029.

Novel role of hematopoietic stem cells in immunologic rejection of malignant gliomas.造血干细胞在恶性胶质瘤免疫排斥反应中的新作用。

Oncoimmunology. 2015 Jan 22;4(3):e994374. doi: 10.4161/2162402X.2014.994374. eCollection 2015 Mar.

Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.异体神经母细胞瘤移植瘤模型中永久性和瞬时性修饰 GD2 嵌合抗原受体 T 细胞对肿瘤控制的性质。

Cancer Immunol Res. 2014 Nov;2(11):1059-70. doi: 10.1158/2326-6066.CIR-14-0051. Epub 2014 Aug 7.

Engineered T cells for cancer treatment.肿瘤治疗用工程化 T 细胞。

Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验